Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study of dolutegravir + lamivudine versus continuing a tenofovir alafenamide-based regimen in virologically suppressed adults with HIV-1
NL-OMON46492Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, lamivudine and tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Virologic failure at Week 48. Started Apr 2018; status: completed.
02
Drugs
dolutegravirlamivudinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON46492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46492.